Table 3.
Survival models for CD68+PD-L1+ and CD8+PD-L1+ for all patients.
| n | Univariate analysis | MVA with CD68+PD-L1+ | MVA with PD-L1+ | MVA with CD8+PD-L1+ | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | HR | 95% CI | p value | ||
| Overall survival | |||||||||||||
| Age (< 55 vs. ≥ 55) | 105 vs. 138 | 0.48 | 0.29–0.80 | 0.004 | 0.46 | 0.26–0.78 | 0.004 | 0.40 | 0.23–0.67 | 0.001 | 0.45 | 0.22–0.93 | 0.031 |
| Size (≤ 20 vs. > 20 mm) | 113 vs. 129 | 0.54 | 0.32–0.89 | 0.016 | 0.53 | 0.31–0.92 | 0.024 | 0.54 | 0.32–0.93 | 0.026 | 0.54 | 0.29–1.04 | 0.066 |
| LN status (neg vs. pos) | 156 vs. 85 | 0.43 | 0.27–0.70 | 0.001 | 0.43 | 0.25–0.73 | 0.002 | 0.44 | 0.26–0.73 | 0.002 | 0.44 | 0.24–0.81 | 0.008 |
| Chemotherapy (yes vs. no) | 174 vs. 58 | 0.49 | 0.30–0.81 | 0.006 | 0.49 | 0.24–1.04 | 0.063 | ||||||
| CD68+PD-L1+ (high vs. low) | 116 vs. 115 | 0.59 | 0.36–0.96 | 0.034 | 0.56 | 0.33–0.95 | 0.030 | – | – | – | – | – | – |
| PD-L1+ (high vs. low) | 122 vs. 121 | 0.60 | 0.36–0.96 | 0.034 | – | – | – | 0.54 | 0.33–0.90 | 0.018 | – | – | – |
| CD8+PD-L1+ (high vs. low) | 104 vs. 103 | 0.82 | 0.47–1.41 | 0.467 | – | – | – | – | – | – | 1.07 | 0.57–1.99 | 0.838 |
| Breast cancer specific survival | |||||||||||||
| Age (< 55 vs. ≥ 55) | 105 vs. 138 | 0.50 | 0.27–0.91 | 0.022 | 0.41 | 0.21–0.77 | 0.005 | 0.55 | 0.25–1.23 | 0.147 | |||
| Size (≤ 20 vs. > 20 mm) | 113 vs. 129 | 0.45 | 0.24–0.85 | 0.013 | 0.51 | 0.26–0.99 | 0.046 | 0.54 | 0.25–1.17 | 0.119 | |||
| LN status (neg vs. pos) | 156 vs. 85 | 0.31 | 0.17–0.55 | < 0.001 | 0.23 | 0.12–0.45 | < 0.001 | 0.30 | 0.16–0.56 | < 0.001 | 0.29 | 0.14–0.60 | 0.001 |
| Chemotherapy (yes vs. no) | 174 vs. 58 | 0.69 | 0.37–1.30 | 0.253 | 0.45 | 0.21–0.96 | 0.039 | 0.60 | 0.23–1.52 | 0.278 | |||
| CD68+PD-L1+ (high vs. low) | 116 vs. 115 | 0.58 | 0.31–1.06 | 0.075 | 0.47 | 0.25–0.88 | 0.018 | – | – | – | – | – | – |
| PD-L1+ (high vs. low) | 122 vs. 121 | 0.60 | 0.33–1.09 | 0.093 | – | – | – | 0.50 | 0.27–0.92 | 0.026 | – | – | – |
| CD8+PD-L1+ (high vs. low) | 104 vs. 103 | 1.01 | 0.52–1.95 | 0.975 | – | – | – | – | – | – | 1.12 | 0.53–2.33 | 0.770 |
LN, lymph node; MVA, multivariate analysis. Univariate and multivariate Cox regression models using a p value threshold of 0.05 for statistical significance, which are labelled in bold. Some multivariate models may not feature all significant p values, [–] indicates the immunophenotype was not significant.